



The Northern Neonatal Network
An Operational Delivery Network
Website - www.nornet.org.uk



Chair: Deborah Jenkins

kindlingltd@msn.com

Clinical Lead: Dr Sundeep Harigopal

sundeep.harigopal@nuth.nhs.uk
P.A. 0191 2825755

Nurse Lead: Lynne Paterson

lynne.paterson@stees.nhs.uk
(01642) 854871

Manager: Martyn Boyd

Northern Neonatal Network, Trust Headquarters (Room 248), Sunderland Royal Hospital,
Kayll Road, Sunderland, SR4 7TP

martyn.boyd@chsft.nhs.uk
Office line (0191) 541 0139
Mobile 07795062535

Consensus statement on management of mothers and their babies at borderline of viability

V2.0 (June 2018)

Due for review – June 2020

Consensus statement on management at borderline of viability

This joint Maternity and Northern Neonatal Network document aims to address the management of women with threatened labour at 22 weeks gestation.

For extremely preterm babies of 24 weeks upwards there is good consensus about giving antenatal steroids and attempting to ensure delivery in a centre capable of level 3 neonatal intensive care. This guidance relates to the management of pregnant women before 24 weeks either going into preterm labour or needing delivery for maternal reasons.

The results from the EPICure2 data suggests there is an increase in the survival and disability free survival in the extreme premature infants born before 26 completed weeks of gestation especially in the 24 and 25 weeks gestation. The observed benefits stem from better antenatal care provided such as use of steroids, use of surfactant and improved postnatal management.

Increasingly the survival at 23 weeks has improved in recent years in some centres however the use of antenatal steroids is varied. Over the 6 years 2006-11, aggregate survival to 1 year for babies at 23 weeks gestation was around 40% in the Northern Neonatal Network. Survival rates at 23 week in one of the NICUs is ~70% in 2016. (3 year rolling average)

There is increasing evidence of benefit in use of antenatal steroids below 24 weeks. In a large prospective cohort study¹ (1993-2009) (N=10541), by the NICHD network published data on the benefits of corticosteroid therapy death or neurodevelopmental impairment in surviving infants born at 23 weeks gestation was significantly lower at 18 to 22 months infants when at least one dose of antenatal steroid therapy was administered [83.4% vs. 90.5%; AOR 0.58 (95% CI 0.42-0.80)].

In a separate retrospective cohort study (N=181), Hayes et al² showed 82% reduction in the odds of death when complete antenatal steroid therapy was administered at 23 weeks of gestation. The multivariable analysis showed decreased odds of death (OR 0.18, 95% CI 0.06-0.54) with no significant differences in the occurrence of NEC or IVH among survivors. In another retrospective study, Abbasi et al³ showed exposure to single course of corticosteroids prior to 24 weeks gestation was associated with reduction in risk of severe IVH and neonatal mortality.

In the light of the current evidence, it is important to have uniformity of approach across the maternity and neonatal networks. After discussion at the maternity and neonatal network meetings it was agreed

- To offer antenatal steroids from 22+5 weeks gestation
- To offer transfer to the woman to a tertiary centre from 22+5 weeks gestation
- To discuss the above with the obstetric and neonatal team at the tertiary centre

The parents' wishes and previous obstetric history play an important role and therefore it is important that a detailed antenatal discussion takes place with the family.


¹ Carlo et al. Association of Antenatal Corticosteroids with Mortality and Neurodevelopmental Outcomes among Infants Born at 22 to 25 Weeks' Gestation. *JAMA*. 2011;306(21):2348-2358

² Hayes EJ, Paul DA, Stahl GE, et al. Effect of antenatal corticosteroids on survival for neonates born at 23 weeks of gestation. *Obstet Gynecol*. 2008;111(4):921-926

³ Abbasi S, Oxford C, Gerdes J, Sehdev H, Ludmir J. Antenatal corticosteroids prior to 24 weeks' gestation and neonatal outcome of extremely low birth weight infants. *Am J Perinatol*. 2010;27(1):61-66

Dr. Sundeep Harigopal (Northern Neonatal Network Clinical Lead), June 2018

Document Control

Document Ref. Number	NNNCS01
Title of document	Consensus statement on management of mothers and their babies at borderline of viability
Original author's names	Dr Sundeep Harigopal
Author's job title	Consultant Neonatologists, RVI (Newcastle)) Clinical Lead for NNN
Department/type	Network guidance
Document status	V2.0 June 2018
Based on	Update to previous agreed consensus statement
Signed off by Board	 D. Jenkins, Network Chair 24/11/14
Publication date	30/07/2018
Next review date	30/07/2020
Distribution	Neonatal & Maternity Networks

Consultation History

Version	Date	Consultation
Draft	October 2014	Maternity Network via Dr Stephen Sturgiss
V 1.0	November 2014	Network Board
V 2.0	June 2018	Update by S. Harigopal, Maternity Network

